Follow-On Biologics Process May Allow Post-Approval Immunogenicity Tests
Executive Summary
A regulatory process for follow-on biologics could allow for post-approval immunogenicity testing, FDA Office of Biotechnology Products Principal Advisor for Regulatory Science & Review Anthony Mire-Sluis, PhD, suggested
You may also be interested in...
Follow-On Biologics Guidance Delay Lauded By Senate Health Cmte. Staffer
FDA should not issue a guidance on follow-on biologics until after Congress has established a regulatory pathway, Senate Health Committee Counsel Steve Irizarry said at an American Conference Institute meeting in New York June 25
Follow-On Biologics Guidance Delay Lauded By Senate Health Cmte. Staffer
FDA should not issue a guidance on follow-on biologics until after Congress has established a regulatory pathway, Senate Health Committee Counsel Steve Irizarry said at an American Conference Institute meeting in New York June 25
GPhA “Generic” Biologics Proposal Includes Directive For FDA Advice
The Generic Pharmaceutical Association is proposing that legislation to create a "generic" biologics process should include a directive to FDA to provide advice to follow-on manufacturers